Atlas Trials

Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

Clinical trial NCT02592785 · COMPLETED

Trial details

NCT number
NCT02592785
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Neoplasms
Start date
2015-12-15
Primary completion
2017-02-05
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.